Israel - hebreiska - Ministry of Health

salomon,levin & elstein ltd - oxaliplatin 5 mg/ml - concentrate for solution for infusion - oxaliplatin - oxaliplatin in combination with 5- fluorouracil (5-fu) and folinic acid (fa) is indicated for : - adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour. - treatment of metastatic colorectal cancer.

Israel - hebreiska - Ministry of Health

salomon,levin & elstein ltd - oxaliplatin 100 mg/vial - powder for solution for infusion - oxaliplatin - oxaliplatin in combination with 5- fluorouracil (5-fu) and folinic acid (fa) is indicated for : - adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour. - treatment of metastatic colorectal cancer.

Israel - hebreiska - Ministry of Health

novapharma ltd - oxaliplatin 50 mg/vial - powder for solution for infusion - oxaliplatin - oxaliplatin in combination with 5- fluorouracil and folinic acid (fa) is indicated for : - adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour .- treatment of metastatic colorectal cancer.

Israel - hebreiska - Ministry of Health

novapharma ltd - oxaliplatin 100 mg/vial - powder for solution for infusion - oxaliplatin - oxaliplatin in combination with 5- fluorouracil and folinic acid (fa) is indicated for : - adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour.- treatment of metastatic colorectal cancer.

Israel - hebreiska - Ministry of Health

novapharma ltd - oxaliplatin 5 mg/ml - concentrate for solution for infusion - oxaliplatin - in combination with 5- fluorouracil and folinic acid (fa) oxaliplatin is indicated for: - adjuvant treatment of stage iii ( duke's c) colon cancer after complete resection of primary tumour - the treatment of metastatic colorectal cancer.

Israel - hebreiska - Ministry of Health

medison pharma ltd - oxaliplatin 5 mg/ml - concentrate for solution for infusion - oxaliplatin - oxaliplatin in combination with 5- fluorouracil and folinic acid (fa), oxaliplatin is indicated for: - adjuvant treatment of stage iii ( duke's c) colon cancer after complete resection of primary tumour - the treatment of metastatic colorectal cancer.

Israel - hebreiska - Ministry of Health

אנדומדיק בע"מ - רופא - נוזלים אינרטיים שקופים בצפיפות גבוהה לשימוש בניתוחי מקטע אחורי בעיניים

Israel - hebreiska - Ministry of Health

m - fast - רופא - קיבועים לעמוד שדרה מותני

Israel - hebreiska - Ministry of Health

abic marketing ltd, israel - gemcitabine as hydrochloride - תרכיז להכנת תמיסה לאינפוזיה - gemcitabine as hydrochloride 40 mg/ml - gemcitabine - gemcitabine - gemcitabine teva® concentrate is indicated for the palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-fu refractory pancreatic cancer.gemcitabine teva® concentrate is indicated for the treatment of patients with bladder cancer at the invasive stage.breast cancer:gemcitabine teva® concentrate in combination with paclitaxel,is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant /neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated.ovarian cancer:gemcitabine teva® concentrate in combination with carboplatin, is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma who have relapsed at least 6 months after platinum-based therapy.

Israel - hebreiska - Ministry of Health

devries & co. ltd - topotecan hydrochloride 1 mg - powder for concentrate for soution for infusion - topotecan - treatment of metastatic carcinoma of the ovary after failure of initial or subsequent therapy. treatment of small cell lung cancer sensitive disease after failure of first line chemotherapy. topotecan in combination with cisplatin is indicated for the treatment of stage iv-b recurrent or persistent carcinoma of the cervix which is not amenable to curative treatment with surgery and/or radiation therapy.